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Background. Candidemia is a common hospital-acquired infection that is associated with high mortality. Diagnosis via blood cultures (BC) is limited by poor sensitivity (50%) and slow turnaround time (2-5 days). T2Candida (T2C) is a newly available rapid test using magnetic resonance that can detect 5 species of Candida from whole blood in < 6 hours with a sensitivity of 91.1%.
Methods. We performed a retrospective analysis of all cases of candidemia detected by BC and/or T2C during 2016 at UAB Medical Center. The test was targeted to ICU patients who had higher risk criteria for candidemia. We collected APACHE II scores at the time of BC or T2C test collection as a surrogate for severity of illness. Other outcomes included 30-day mortality and time to initiation of therapy (TTT).
Results. We identified 139 patients with candidemia, defined as a positive BC (BC+) and/or positive T2C (T2C+). Performance of a single test led to diagnosis in 103 patients (74%). On initial diagnosis if both a BC and T2C were performed within a 24 hour interval, patients were grouped based on the results of both tests. 36 patients (26%) had both tests performed: 8/36 (22%) were concordant (BC+/T2C+) and 28/36 (78%) discordant. 23/28 patients (82%) with discordance were BC-/T2C+ and the remaining 5 were BC+/T2C-. The difference in APACHE II scores and 30-day mortality rate of BC+ patients (13.6, 0.36) and T2C+ patients (16.4, 0.46) were not significant (P-values 0.06 and 0.29, respectively); the difference in TTT between BC+ patients (1.6 day) and T2C+ patients (0.1 day) was statistically significant (P-value < 0.00001).
Conclusion. T2C demonstrated excellent sensitivity (88.6%) in a 'real world' setting focused in the ICU. We observed a significant reduction in TTT associated with the T2C assay, but did not observe an improvement in survival with earlier therapy for candidemia defined as a T2C+. Patients with T2C+ had higher APACHE II scores suggesting biased testing towards sicker patients. We cannot explain the large number of discordant results (BC−/T2C+, BC+/T2C−), but hypothesize that T2C+ may be a more sensitive marker for invasive candidiasis/candidemia. These data strongly endorse the need for a large, prospective, multicenter study exploring the use of T2C vs. standard of care in the diagnosis and management of this disorder. Background. Improved diagnostics are needed for the management of invasive fungal infections. Standard sputum cultures have a low yield in the detection of mold. Conventionally only a fraction of the specimen is cultured. We studied the performance of high-volume cultures (HVCs) where the entire specimen is plated on Sabouraud agar (SA).
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Methods. Specimens were collected at our center from January 2015 through February 2017. For conventional culture, sputum was homogenized by mixing with an equal volume of 0.1% dithiothreitol solution and diluted 500-fold in sterile water. Ten μL of the diluted specimen was cultured on SA (2 plates) and incubated at 37°C and 45°C for up to 5 days. For HVC, the entire undiluted specimen (up to 1 mL) was cultured on SA (up to 2 plates) and incubated at 30°C for up to 14 days.
Results. We studied 306 paired specimens that were collected for both conventional culture and HVC on the same day. A total of 139 patients with positive cultures had the following conditions: chronic pulmonary aspergillosis (58%), allergic bronchopulmonary aspergillosis/severe asthma with fungal sensitization (27%), Aspergillus bronchitis (9%), cystic fibrosis/bronchiectasis (6%).
Aspergillus was recovered by HVC in 114 specimens that had no mold growth by conventional culture. The same Aspergillus species was recovered by both HVC and conventional culture in 50 paired specimens. For 142 specimens there was no Aspergillus growth by HVC (Penicillium spp. grew in 4). For two of the negative HVC specimens A. fumigatus grew by conventional culture. The following species were recovered by HVC: A. fumigatus (80%), A. niger (10%), A. flavus (3%), other (7%). Susceptibility testing (EUCAST standard) was performed for 127 isolates of A. fumigatus. Rates of antifungal resistance were as follows: itraconazole 28%, voriconazole 19%, posaconazole 28%, isavuconazole 32%, amphotericin B 8%. Pan-azole resistance was detected in 17%. If HVCs were not performed, resistance to at least one of the antifungals would have been missed in 18/37 (49%) of cases.
Conclusion. The recovery rate of Aspergillus spp. is significantly higher for HVCs compared with conventional cultures and this can impact patient care. HVCs can be performed in any microbiology laboratory without the need for additional tools. Background. Candida auris is now recognized worldwide as a virulent pathogen that is difficult to manage, resulting in high mortality rates. The majority of C.auris isolates have exhibited resistance to one or more antifungal agents. Nosocomial infections caused by C.auris are growing due to the increasing rate of colonization and environmental causes. The diagnostic tests available for the identification of C. auris are limited to date. Additionally, microbiological cultures and subsequent identification of Candida species require 2-5 days, and have a sensitivity of approximately 50%. Accurate diagnosis of a C. auris infection is also hampered by misidentification of C. auris as other species, commonly C. haemulonii and Saccharomyces cerevisiae.
Here we evaluate the use of the T2MR platform for the highly sensitive, rapid species level identification of C. auris, C. lusitaniae and C. haemulonii in whole blood samples.
